Skip to main content

Coagulation Protein Disorders

Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)
NCT01053169 | PHASE 2 | OBSERVATIONAL

Beriplex® P/N is made from human plasma (the liquid part of the blood) and contains the coagulation factors II, VII, IX and X which are important for blood clotting (coagulation). Lack of any of these factors means that blood does not clot as quickly as it should and so there is an increased tendency to bleed. This observational study was designed to evaluate the effectiveness of Beriplex® P/N in the prevention (prophylaxis) and treatment of bleeding during surgery (perioperative bleeding) in a routine clinical setting.

Trial Information
6 Sites
445 Participants
Recruiting
16 Years to 75 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Royal Blackburn Hospital
Blackburn,United Kingdom
Blackpool
Blackpool,United Kingdom,FY38NR
Addenbrokes
Cambridge,United Kingdom,CB233RE
Royal Free Hospital
London,United Kingdom
Derriford Hospital
Plymouth,United Kingdom
Southhampton General Hospital
Southhampton,United Kingdom

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov